Imprimis has received a patent for its MKO Melt compounded formulation from the U.S. Patent and Trademark Office, according to a press release.
The MKO Melt (midazolam, ketamine and ondansetron) is a nonopioid, IV-free sublingual formulation for sedation.
“We are pleased to have been granted this patent which covers our MKO Melt formulation and a variety of other versions of midazolam and ketamine combinations we intend to make available to address unmet patient needs,” Mark L. Baum, Imprimis CEO, said in the release.
The MKO Melt has been used in (Read more...)
Uncategorized